Synthetic anti-infective developer Recce Pharmaceuticals Ltd (ASX:RCE) has made inroads for recognition of its RECCE® 327 Gel (or R327G) as a topical treatment for burn wound infections, gaining a US$2 million grant from the US Department of Defense to accelerate its development. The funding will be invested in developing R327G for the specific treatment of these wound infections in a military setting, with the treatment of downstream bacteria complications such as sepsis also a focus. The company will be aiming to build on this recognition, with this gel to be considered a replacement for tra…